These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30359123)

  • 1. Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Wanner C; von Eynatten M; Zinman B
    Circulation; 2018 Aug; 138(8):850-851. PubMed ID: 30359123
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter by Tampakis et al Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Tampakis A; Tampaki EC; Gürke L
    Circulation; 2018 Aug; 138(8):848-849. PubMed ID: 30359125
    [No Abstract]   [Full Text] [Related]  

  • 3. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter by Koh Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Koh KK
    Circulation; 2018 Aug; 138(8):846-847. PubMed ID: 30359121
    [No Abstract]   [Full Text] [Related]  

  • 5. In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization.
    Moist L
    Ann Intern Med; 2018 May; 168(10):JC52. PubMed ID: 29800428
    [No Abstract]   [Full Text] [Related]  

  • 6. Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk".
    Zinman B; Inzucchi SE; Diener HC
    Stroke; 2017 Sep; 48(9):e256-e257. PubMed ID: 28701577
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter by Tampaki et al Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk".
    Tampaki EC; Tampakis A; Gürke L
    Stroke; 2017 Sep; 48(9):e255. PubMed ID: 28701575
    [No Abstract]   [Full Text] [Related]  

  • 8. Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page.
    Plutzky J; Bakris G
    Circulation; 2018 Jan; 137(2):130-133. PubMed ID: 29311346
    [No Abstract]   [Full Text] [Related]  

  • 9. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    Wanner C; Inzucchi SE; Lachin JM; Fitchett D; von Eynatten M; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; Zinman B;
    N Engl J Med; 2016 Jul; 375(4):323-34. PubMed ID: 27299675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
    Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
    Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 y.
    Kwong YD; Hsu CY
    Ann Intern Med; 2023 Mar; 176(3):JC26. PubMed ID: 36877974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
    Barnett AH; Mithal A; Manassie J; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Lancet Diabetes Endocrinol; 2014 May; 2(5):369-84. PubMed ID: 24795251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease.
    Scheen AJ
    Evid Based Med; 2017 Apr; 22(2):69-70. PubMed ID: 28159856
    [No Abstract]   [Full Text] [Related]  

  • 14. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Edwards JL
    N Engl J Med; 2016 Mar; 374(11):1093. PubMed ID: 26981943
    [No Abstract]   [Full Text] [Related]  

  • 15. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Rosenstein R; Hough A
    N Engl J Med; 2016 Mar; 374(11):1093-4. PubMed ID: 26981944
    [No Abstract]   [Full Text] [Related]  

  • 16. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Fischereder M; Schönermarck U
    N Engl J Med; 2016 Mar; 374(11):1092-3. PubMed ID: 26981942
    [No Abstract]   [Full Text] [Related]  

  • 17. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Sarafidis PA; Tsapas A
    N Engl J Med; 2016 Mar; 374(11):1092. PubMed ID: 26981941
    [No Abstract]   [Full Text] [Related]  

  • 18. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B; Lachin JM; Inzucchi SE
    N Engl J Med; 2016 Mar; 374(11):1094. PubMed ID: 26981940
    [No Abstract]   [Full Text] [Related]  

  • 19. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
    Zinman B; Inzucchi SE; Lachin JM; Wanner C; Fitchett D; Kohler S; Mattheus M; Woerle HJ; Broedl UC; Johansen OE; Albers GW; Diener HC;
    Stroke; 2017 May; 48(5):1218-1225. PubMed ID: 28386035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.
    Fitchett D; Inzucchi SE; Lachin JM; Wanner C; van de Borne P; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; George JT; Zinman B;
    J Am Coll Cardiol; 2018 Jan; 71(3):364-367. PubMed ID: 29348030
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.